Drug Trial Radar · NCT05562466
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
May 11, 2023
Primary completion
Feb 1, 2028
Study completion May 30, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the superiority in terms of efficacy and evaluate the safety of QMF149 (indacaterol (acetate) / mometasone (furoate)) compared to budesonide in children from 6 to less than 12 years of age with asthma. * The study duration will be up to 37 weeks including an investigational treatment duration of 12 weeks and a comparator treatment duration of 12 weeks. * The visit frequency will be 3 weeks for screening, run-in and wash-out period, 6 weeks interval for visits during each treatment period, 30 days for safety follow-up.
Conditions
- Asthma
Interventions
QMF149Drug
QMF149 75/40 μg o.d via Breezhaler
BudesonideDrug
Budesonide 200 μg o.d via Breezhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in trough FEV1Time frame: Week 12 of each treatment period
Locations
65 sites in 17 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
CABA, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
CABA, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
CABA, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
Mendoza, Mendoza Province, Argentina · Recruiting
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina · Recruiting
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina · Recruiting
Novartis Investigative Site
Graz, Austria · Withdrawn
Novartis Investigative Site
Salzburg, Austria · Withdrawn
Novartis Investigative Site
Sankt Pölten, Austria · Withdrawn
Novartis Investigative Site
Brasília, Federal District, Brazil · Recruiting
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Novartis Investigative Site
Sorocaba, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Rousse, Bulgaria · Recruiting
Novartis Investigative Site
Sevlievo, Bulgaria · Recruiting
Novartis Investigative Site
Bucaramanga, Santander Department, Colombia · Recruiting
Novartis Investigative Site
Ibague, Tolima Department, Colombia · Recruiting
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia · Recruiting
Novartis Investigative Site
Plzen Bory, Czechia · Withdrawn
Novartis Investigative Site
Prague, Czechia · Withdrawn
Novartis Investigative Site
Athens, Greece · Recruiting
Novartis Investigative Site
Chaïdári, Greece · Withdrawn
Novartis Investigative Site
Heraklion Crete., Greece · Recruiting
Novartis Investigative Site
Pátrai, Greece · Active not recruiting
Novartis Investigative Site
Thessaloniki, Greece · Recruiting
Novartis Investigative Site
Guatemala City, Guatemala · Recruiting
Novartis Investigative Site
Guatemala City, GTM, Guatemala · Recruiting
Novartis Investigative Site
Budapest, Hungary · Recruiting
Novartis Investigative Site
Gödöllő, Hungary · Recruiting
Novartis Investigative Site
Szeged, Hungary · Recruiting
Novartis Investigative Site
Szigetvár, Hungary · Recruiting
Novartis Investigative Site
Naples, Italy · Recruiting
Novartis Investigative Site
Brescia, BS, Italy · Withdrawn
Novartis Investigative Site
Catania, CT, Italy · Recruiting
Novartis Investigative Site
Florence, FI, Italy · Withdrawn
Novartis Investigative Site
Pavia, PV, Italy · Withdrawn
Novartis Investigative Site
Roma, RM, Italy · Recruiting
Novartis Investigative Site
Querétaro, Mexico · Recruiting
Novartis Investigative Site
Guadalajara, Jalisco, Mexico · Recruiting
Novartis Investigative Site
Guadalajara, Jalisco, Mexico · Recruiting
Novartis Investigative Site
San Juan del Río, Querétaro, Mexico · Recruiting
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.